Prognostic value of apoptosis-related markers in urothelial cancer of the upper urinary tract

Human Pathology

Volumn 40, Issue 5, 2009, Pages 668-677

  Jeong, In Gab ^a   Kim, Sung Han ^a   Jeon, Hwang Gyun ^a   Kim, Baek Hee ^a   Moon, Kyung Chul ^a   Lee, Sang Eun ^b   Lee, Eunsik ^a  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

Apoptosis; Carcinoma; Kidney pelvis; Prognostic factor; Ureter

Indexed keywords

CASPASE 3; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; SURVIVIN; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; NICK END LABELING; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; URINARY TRACT CARCINOMA;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; KAPLAN-MEIERS ESTIMATE; KIDNEY NEOPLASMS; KIDNEY PELVIS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URETERAL NEOPLASMS;

EID: 64049102281     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2008.10.010     Document Type: Article

References (32)

1. Flanigan R.C. Urothelial tumors of the upper urinary tract. In: Wein A.J., Kavoussi L.R., Novick A.C., Partin A.W., and Peters C.A. (Eds). Campbell-Walsh Urology. 9th ed. (2007), WB Saunders, Philadelphia 1638
2. Hall M.C., Womack S., Sagalowsky A.I., Carmody T., Erickstad M.D., and Roehrborn C.G. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 52 (1998) 594-601
3. Nakanishi K., Tominaga S., Kawai T., Torikata C., Aurues T., and Ikeda T. Expression of bcl-2 oncoprotein in transitional cell carcinoma of the upper urinary tract. Virchows Arch 432 (1998) 445-450
4. Kamai T., Takagi K., Asami H., Ito Y., Arai K., and Yoshida K.I. Prognostic significance of p27Kip1 and Ki-67 expression in carcinoma of the renal pelvis and ureter. BJU Int 86 (2000) 14-19
5. Nakanishi K., Tominaga S., Hiroi S., et al. Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract. Virchows Arch 441 (2002) 559-563
6. Langner C., von Wasielewski R., Ratschek M., Rehak P., and Zigeuner R. Expression of p27 and its ubiquitin ligase subunit Skp2 in upper urinary tract transitional cell carcinoma. Urology 64 (2004) 611-616
7. Zigeuner R., Tsybrovskyy O., Ratschek M., Rehak P., Lipsky K., and Langner C. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. Urology 63 (2004) 1079-1083
8. Fromont G., Rouprêt M., Amira N., et al. Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma. Eur Urol 48 (2005) 764-770
9. Miyata Y., Kanda S., Nomata K., Eguchi J., and Kanetake H. Expression of cyclooxygenase-2 and EP4 receptor in transitional cell carcinoma of the upper urinary tract. J Urol 173 (2005) 56-60
10. Kashibuchi K., Tomita K., Schalken J.A., et al. The prognostic value of E-cadherin, alpha-, beta-, and gamma-catenin in urothelial cancer of the upper urinary tract. Eur Urol 49 (2006) 839-845
11. Karam J.A., Lotan Y., Karakiewicz P.I., et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 8 (2007) 128-136
12. Malats N., Bustos A., Nascimento C.M., et al. p53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 6 (2005) 678-686
13. Rey A., Lara P.C., Redondo E., Valdes E., and Apolinario R. Overexpression of p53 in transitional cell carcinoma of the renal pelvis and ureter. Relation to tumor proliferation and survival. Cancer 79 (1997) 2178-2185
14. Nakanishi K., Hiroi S., Tominaga S., et al. Expression of hypoxia-inducible factor-1alpha protein predicts survival in patients with transitional cell carcinoma of the upper urinary tract. Clin Cancer Res 11 (2005) 2583-2590
15. Kluck R.M., Bossy-Wetzel E., Green D.R., and Newmeyer D.D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275 (1997) 1132-1136
16. Vollmer R.T., Humphrey P.A., Swanson P.E., Wick M.R., and Hudson M.L. Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2. Cancer 82 (1998) 715-723
17. Pollack A., Wu C.S., Czerniak B., Zagars G.K., Benedict W.F., and McDonnell T.J. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res 3 (1997) 1823-1829
18. Maluf F.C., Cordon-Cardo C., Verbel D.A., et al. Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment. Ann Oncol 17 (2006) 1677-1686
19. Korkolopoulou P., Lazaris A.C., Konstantinidou A.E., et al. Differential expression of bcl-2 family proteins in bladder carcinomas. Relationship with apoptotic rate and survival. Eur Urol 41 (2002) 274-283
20. Glick S.H., Howell L.P., and White R.W. Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder. J Urol 155 (1996) 1754-1757
21. Gonzalez-Campora R., Davalos-Casanova G., Beato-Moreno A., et al. BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma. Cancer Lett 250 (2007) 292-299
22. Hussain S.A., Ganesan R., Hiller L., et al. Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder. Br J Cancer 88 (2003) 586-592
23. Burton P.B., Anderson C.J., and Corbishly C.M. Caspase 3 and p27 as predictors of invasive bladder cancer. N Engl J Med 343 (2000) 1418-1420
24. Gazzaniga P., Gradilone A., Giuliani L., et al. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol 14 (2003) 85-90
25. Ambrosini G., Adida C., and Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3 (1997) 917-921
26. Swana H.S., Grossman D., Anthony J.N., Weiss R.M., and Altieri D.C. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 341 (1999) 452-453
27. Ku J.H., Kwak C., Lee H.S., Park H.K., Lee E., and Lee S.E. Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. J Urol 171 (2004) 631-635
28. Shariat S.F., Ashfaq R., Karakiewicz P.I., Saeedi O., Sagalowsky A.I., and Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 109 (2007) 1106-1113
29. Smith S.D., Wheeler M.A., Plescia J., Colberg J.W., Weiss R.M., and Altieri D.C. Urine detection of survivin and diagnosis of bladder cancer. JAMA 285 (2001) 324-328
30. Shariat S.F., Casella R., Khoddami S.M., et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 171 (2004) 626-630
31. Lipponen P.K., and Aaltomaa S. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol 173 (1994) 333-339
32. King E.D., Matteson J., Jacobs S.C., and Kyprianou N. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. J Urol 155 (1996) 316-320